Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
The DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors are highly safe and efficient gene delivery vehicles. However, numerous challenges in vector design remain, including neutralizing antibody responses, tissue transport and infection of resistant cell types. Changes must be made to the viral capsid to overcome these problems; however, very often insufficient information is available for rational design of improvements. We therefore applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of adeno-associated virus (AAV) 2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum. This approach, which can be extended to additional gene delivery challenges and serotypes, directs viral evolution to generate 'designer' gene delivery vectors with specified, enhanced properties.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [68]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [194]
In the citing paper
“The best-performing variants selected from this screen were reported to evade antibodies and enhance the gene expression [88].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [88]
Citations
Cites
Rapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Yeast surface display for screening combinatorial polypeptide libraries
Boder, E. T., & Wittrup, K. D. (1997) · Nature Biotechnology · doi:10.1038/nbt0697-553 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo
Lai, K., Kaspar, B. K., Gage, F. H., & Schaffer, D. V. (2003) · Nature Neuroscience · doi:10.1038/nn983 · Cited by 799
Self-citationRabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Cited by
Items 401–500 of 535
Zarbin, M. A., Leary, J. F., Montemagno, C. D., Ritch, R. H., & Humayun, M. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00036-9 · Cited by 7
Gene delivery into cells and tissues
Nelson, C. E., Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00030-7 · Cited by 9
Cong, W., Shi, Y., Qi, Y., Wu, J., Gong, L., & He, M. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108629 · Cited by 8
Live-cell Microarray Surface Coatings Supporting Reverse Transduction by Adeno-Associated Viruses
McConnell, K. I., Schweller, R. M., Diehl, M. R., & Suh, J. (2011) · BioTechniques · doi:10.2144/000113748 · Cited by 6
Cai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
Advances in Engineered Virus-Like Particles for Genome Editing and Therapy
Son, S. H., Woo, S., Choi, A., Ahn, S., & Yoo, H. C. (2026) · BioDrugs · doi:10.1007/s40259-026-00767-z · Cited by 5
“…identity of each capsid variant is inherently preserved through the packaged viral genome, which enables a direct linkage of phenotype to genotype and facilitates the recovery of high-performing variants [79]. eVLPs, in contrast, lack a viral genome, rendering these standard methods inapplicable.”
Selective Anti-AAV Antibody Depletion by Hemapheresis and Immunoadsorption
Orlowski, A., & Weber, T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2707-5_18 · Cited by 5
Viral Vector Technologies and Strategies: Improving on Nature
Croze, R. H., Kotterman, M. A., Burns, C. H., Schmitt, C. E., Quezada, M., Schaffer, D. V., Kirn, D. H., & Francis, P. J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000361 · Cited by 5
Self-citationPiletska, E. V., Veron, P., Bertin, B., Mingozzi, F., Jones, D. J. L., Norman, R. L., Earley, J., Karim, K., García‐Cruz, Á., & Piletsky, S. A. (2023) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2023.102691 · Cited by 5
Considerations for the Use of Viral Vectors in Nonhuman Primates
Bohlen, M. O., & Tremblay, S. (2023) · Neuromethods · doi:10.1007/978-1-0716-2918-5_16 · Cited by 6
Zhang, H. S., Kim, E., Lee, S., Ahn, I., & Jang, J. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.10.004 · Cited by 5
Inherited diseases of photoreceptors and prospects for gene therapy.
Montana, C., & Corbo, J. (2008) · Pharmacogenomics (London) · doi:10.2217/14622416.9.3.335 · Cited by 7
Evaluating eUniRep and other protein feature representations for in silico directed evolutionPreprint
Favor, A., & Jayapurna, I. (2020) · doi:10.22541/au.159683529.96283070 · Cited by 4
Reprogramming Adeno-Associated Virus Tropism Via Displayed Peptides Tiling Receptor-LigandsPreprint
Portell, A. J., Ford, K. M., Suhardjo, A., Rainaldi, J., Bublik, M. N., Sanghvi, M., Kumar, A., Wing, M. K., Palmer, N. D., Le, D. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.26.509383 · Cited by 5
Retinal Penetrating Adeno-Associated Virus
Kumar, B., Mishra, M., Cashman, S. M., & Kumar‐Singh, R. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.10.30 · Cited by 5
“The most common approach is library screening, 6 whereby a highly diverse group of peptides are encoded into an exposed loop of an AAV capsid and such AAV libraries undergo multiple rounds of enrichment for infectivity of the outer retina following intravitreal injection.”
BackgroundReprogramming the brain with synthetic neurobiology
Gardner, E. C., & Ellington, A. D. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.10.013 · Cited by 4
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch37 · Cited by 5
Updated analysis to reject the laboratory-engineering hypothesis of SARS-CoV-2
Wu, F. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115481 · Cited by 8
Rapti, K., Hajjar, R. J., & Weber, T. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-891-7_12 · Cited by 4
Recent highlights and advances in cardiac gene therapy.
Oh, J. G., & Ishikawa, K. (2019) · PubMed · Cited by 4
Future of Cellular and Molecular Diagnostics
Raghavendra, P. B., & Pullaiah, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813679-9.00008-7 · Cited by 5
Gene Therapy Today and Tomorrow
Lundstrom, K. H. (2019) · Diseases · doi:10.3390/diseases7020037 · Cited by 7
“Another approach has been to introduce mutations into the AAV structural genes by error prone PCR and by generating AAV particles with chimeric capsids, which show 100-fold higher resistance to neutralizing antibodies [72].”
BackgroundImmunogenicity of Gene and Cell Therapies
Hofman, K., Jangied, P., & Balu‐Iyer, S. V. (2026) · BioDrugs · doi:10.1007/s40259-025-00756-8 · Cited by 6
“For these reasons, alternative AAVs are being developed to evade antibodies to naturally occurring AAV while providing similar or increased transduction [42, 43].”
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
Advances in endothelial cell targeting by AAV vectors
Cichoń, M., Jozkowicz, A., & Grochot‐Przeczek, A. (2026) · Acta Biochimica Polonica · doi:10.3389/abp.2026.15740 · Cited by 5
Gene and cell-based therapies for retinal and optic nerve disease
Esposito, E. P., Han, I. C., & Johnson, T. V. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00016-2 · Cited by 5
Stem Cell Vaccination Against Cancer: Fighting Fire With Fire?
Zwaka, T. P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.287 · Cited by 3
AAV shuffles to the liver: commentary on Lisowski et al.
Schaffer, D. V. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.6 · Cited by 3
Self-citationGene Therapy: Use of Viruses as Vectors
Nance, M. E., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95711-8 · Cited by 3
Artificial Intelligence-Mediated Computer-Aided Design of Viral Gene Therapies
Daneshvar, A., & Lukianov, S. N. (2023) · GEN Biotechnology · doi:10.1089/genbio.2023.0014 · Cited by 3
“26,49,50 Manufacturing and scalability.”
Liu, L., Xu, B., Chen, L., Liu, J., Liu, W. Y., Xue, F., Feng, S., Jiang, E., Han, M., Shao, W., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101245 · Cited by 3
A Hitchhiker’s Guide to the Selection of Viral Vectors for Optogenetic Studies
Thompson, K. R., & Towne, C. L. (2017) · Neuromethods · doi:10.1007/978-1-4939-7417-7_1 · Cited by 4
Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges
Diallo, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00007-1 · Cited by 4
Capsid modification of adeno-associated virus and tumor targeting gene therapy
Xu, Z., Zhou, X., Shi, W., & Qian, Q. (2008) · 中国科学通报:英文版 · doi:10.1007/s11434-008-0487-y · Cited by 4
Viral Vectors for Gene Delivery
Dismuke, D. J., Gray, S. J., Hirsch, M. L., Samulski, R. J., & Muzyczka, N. (2010) · Royal Society of Chemistry eBooks · doi:10.1039/9781849732239-00338 · Cited by 3
Trends in orally viral vector gene delivery and therapy
Xie, J., & Xu, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-47720-8.00006-7 · Cited by 6
2.202 – Engineering Viruses For Gene Therapy
Bergen, J., & Schaffer, D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00061-1 · Cited by 2
Self-citationAdeno-Associated Virus and AAV Vectors for Gene Delivery
Carter, B. (2015) · CRC Press eBooks · doi:10.1201/b18002-6 · Cited by 3
An Expanded Toolbox for Versatile Chemical Editing of Adeno‐Associated Virus
Pham, Q. T., Glicksman, J., Han, B., Koo, D., Loynd, C., Roy, S. J. S., & Chatterjee, A. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202516157 · Cited by 2
Barethiya, S., Huang, J., Stumpf, C., Liu, X., Guan, H., & Chen, J. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013728 · Cited by 4
“Understanding the protein sequence-to-function relationship, that is, how sequence governs their biological functions, is a fundamental problem central to the studies of protein evolution, diagnosis of genetic disease, and protein engineering and design [1–4].”
Local gene editing of fibroblasts in tumors reveals a new cancer-associated fibroblast state
Kuhn, N. F., Zaleta-Linares, I., Hu, K. H., Courau, T., Davidson, B. R., Tam, T., Chu, C.-W., Kinet, M., Rosenblum, M. D., Combes, A. J., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20251228 · Cited by 5
Enhanced cellular secretion of AAV2 by expression of foreign viral envelope proteins
Kotterman, M. A., Koerber, J. T., Nam, J.-S., Cho, Y.-H., Kim, S., Jang, J.-H., & Lim, K. (2014) · Biochemical Engineering Journal · doi:10.1016/j.bej.2014.09.015 · Cited by 2
Self-citationLarge Virus for an Even Bigger Task: Can the Mimivirus Close the Gene-Therapy Vector Void?
Velthuis, A. J. W. T. (2009) · Future Virology · doi:10.2217/fvl.09.2 · Cited by 2
Evolution of Organic Solvent-Resistant DNA Polymerases
Elias, M., Guan, X., Hudson, D., Bose, R., Kwak, J., Petrounia, I. P., Touah, K., Mansour, S., Peng, Y., Errasti, G., et al. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00515 · Cited by 2
Bleomycin promotes rAAV2 transduction via DNA-PKcs/Artemis-mediated DNA break repair pathways
Huang, X., Wang, X., Sun, Y., Li, L., Li, A., Xu, W., Xie, X., & Diao, Y. (2023) · Virology · doi:10.1016/j.virol.2023.109959 · Cited by 2
Designing molecules: directing stem cell differentiation
Thanaskody, K., Natashah, F. N., Nordin, F., Zaman, W. S. W. K., & Tye, G. J. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1396405 · Cited by 4
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Challenges in Humoral Immune Response to Adeno-Associated Viruses Determination
Naumova, D. A., Krokunova, T., Maksimov, D. O., Mityaeva, O. N., Astakhova, E. A., & Volchkov, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020816 · Cited by 3
“This is highly preferred in studies in which, for example, chimeric AAVs are developed with the purpose of evading pre-existing humoral responses [49,86–88].”
Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery
Henshey, B., Carneiro, A., Lei, K., Schaffer, D. V., & Boulis, N. M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.004 · Cited by 3
Self-citationKnapman, F. L., Cohen, E. M., Kulaga, T., Lovell, N. H., Lisowski, L., Burke, P. G. R., & Bilston, L. E. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101559 · Cited by 2
“19,20 26–28 Clinically, this has the potential to reduce therapeutic viral doses and to lower the risk of immune responses and serious adverse events.”
Gene Therapy for Neovascular Macular Degeneration, Diabetic Retinopathy, and Diabetic Macular Edema
Mellen, P. L., & Heier, J. S. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000382 · Cited by 2
Jäschke, N. M., & Büning, H. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.04.002 · Cited by 2
AAV-Based Targeting Gene Therapy
Shi, W., Yu, M., & Qian, Q. (2008) · American Journal of Immunology · doi:10.3844/ajisp.2008.51.65 · Cited by 2
GDNF and AADC Gene Therapy for Parkinson’s Disease
Bankiewicz, K. S., Sebastián, W. S., Samaranch, L., & Forsayeth, J. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_4 · Cited by 2
Development of Next-Generation Muscle Gene Therapy AAV Vectors
Nance, M. E., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_11 · Cited by 2
Viral vectors for gene delivery
Liang, K. J., & Samulski, R. J. (2015) · doi:10.4155/fseb2013.14.165 · Cited by 2
Merdler-Rabinowicz, R., Dadush, A., Patiyal, S., Rajagopal, P. S., Daya, G. N., Ben‐Aroya, S., Schäffer, A. A., Eisenberg, E., Ruppin, E., & Levanon, E. Y. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf016 · Cited by 2
“Delivering only the programmed chemically modified oligonucleotide to any target cell eliminates the need for an external viral vector or plasmid to insert the enzyme [ 12 ], thereby also reducing the immunogenic response to foreign components.”
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
4.33 Engineering Viruses For Gene Therapy
Bergen, J., & Schaffer, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100691-7.00167-1 · Cited by 1
Self-citationViral Vectors for Muscle Gene Therapy
Wang, D., Brown, A., & Gao, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_10 · Cited by 1
Determination of AAV properties by single amino acids: Go(o)d is in the details
Maiakovska, O., Baumgartl, C., & Grimm, D. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.09.006 · Cited by 1
“, heparin binding or antibody evasion.(5) A powerful permutation of this strategy by the Nakai lab introduced DNA barcoding technology into the AAV field and showcased its potential through massively parallel screening of a double-”
MethodPhage design and directed evolution to evolve phage for therapy
Arora, P., Jain, A., & Kumar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.03.019 · Cited by 1
Engineered Bioactive Molecules
Gersbach, C. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00164-1 · Cited by 1
Gene Therapy for Human Diseases: Recent Achievements and Near-Term Development Prospects
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., & Yusupov, F. A. (2022) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2022-12-5-363-369 · Cited by 2
PHYSIOCHEMICAL STABILITY AND MASS SPECTROMETRIC ANALYSIS OF GEMINI SURFACTANT-BASED LIPOPLEXES
Mohammed‐Saeid, W. (2012) · University Library - University of Saskatchewan (University of Saskatchewan) · Cited by 1
Viral‐Mediated Delivery of shRNA and miRNA
Manfredsson, F. P. (2013) · Wiley eBooks · doi:10.1002/9781118610749.ch11 · Cited by 2
Reshaping AAV vectors for liver gene therapy
Kühnel, F., & Kubicka, S. (2008) · Hepatology · doi:10.1002/hep.22590 · Cited by 1
Gong, H., Yuan, N., Shen, Z., Tang, C., Shipp, S. D., Qian, L., Lu, Y., Andolina, I. M., Zhang, S., Wu, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.08.139667 · Cited by 1
“…with superior efficacy have been engineered through capsid transformation (Broekman et al., 2006), amino acid mutation (Zhong et al., 2008), domain/subunit swapping (Rabinowitz et al., 2004), or screened from mutant capsid libraries (Deverman et al., 2016; Maheshri et al., 2006; Yang et al., 2009).”
BackgroundVorobieva, I., Luchner, M., Friedrichsen, H., Makkar, R., Chester, S., Haughton, E., Conceiao, M., Steel, H., Sanders, S. J., Wood, M. P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.12.693981 · Cited by 2
“Another approach to enhance the EV encapsulation efficiency of AAVs is directed evolution, which has been successfully adopted to engineer AAV variants with enhanced tissue tropism 18 and immune evasion properties 19 .”
Askou, A. L., & Corydon, T. J. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2389-2_3
Improving lentiviral vector-mediated gene transfer by understanding cellular barriers
Oakland, M., McCray, P. B., Maury, W. J., Davidson, B. L., Klingelhutz, A. J., & Perlman, S. M. (2013) · doi:10.17077/etd.f63i1jvz
The State of the Art and Future of Gene Medicines
Jacobs, F., Gordts, S. C., & Geest, B. D. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse515 · Cited by 1
Strategies for improving adeno-associated viral infection of airway epithelial cells
Dickey, D. D. (2012) · doi:10.17077/etd.m1aiqczb
“The rcAAV library and rAAV vectors were packaged and purified via iodixanol gradient centrifugation as previously described (92, 132).”
BackgroundMethodInfluentialBelhoul‐Fakir, H. (2014) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17008231.v1
“4) containing mutations at key antigenic sites (Maheshri et al., 2006).”
BackgroundBionanoparticles and their Biomedical Applications
Lee, L. A., Barnhill, H. N., & Wang, Q. (2003) · Wiley eBooks · doi:10.1002/9783527610419.ntls0119
Steines, B. R., Zabner, J., Meier, J. L., Adams, C. M., McCray, P. B., & Yeaman, C. A. (2015) · doi:10.17077/etd.tdj11wfe
Generation of enhanced gene delivery vectors by directed evolution of adeno-associated virus
Endell, J. (2006) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.5436
In Silico Simulations For Dna Shuffling Experiments
Montera, L. (2010) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.1328631
Nakai, H. (2009) · Drug Delivery System · doi:10.2745/dds.24.582 · Cited by 1
Advances in homology directed genetic engineering of human pluripotent and adult stem cells
Ramamoorthi, K., Curtis, D., & Asuri, P. (2013) · World Journal of Stem Cells · doi:10.4252/wjsc.v5.i4.98
Directed evolution of designer vectors
Whalley, K. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1999
Yu, C.-Y., Wang, B., Wang, Z., Cao, Z., Li, J., & Xiao, X. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.556
Development of a Ribozyme Gene Therapy Against Herpes Simplex Virus Type I (HSV-1) Infection
Liu, J., Bloom, D. C., Lewin, A. S., Tuli, S. S., Ghivizzani, S. C., & Schultz, G. S. (2007) · Investigative Ophthalmology & Visual Science
Davis, A. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Towards therapeutic gene delivery to human cancer cells : targeting and entry of baculovirus
Mäkelä, A. R. (2008) · Jyväskylä University Digital Archive (University of Jyväskylä) · Cited by 1
Novel AAV-mediated Therapeutic Strategies for Epilepsy
Foti, S. B. (2008) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/wakz-r188
Engineering magnetic viral nanoheaters for targeted hyperthermia treatment of cancer
Horn, K. (2009) · Rice Research Repository (Rice University)
Mitchell, A. M. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/f5kg-n202
Novel Approaches for the Eradication Of HIV Latently Infected Cells
Ali, S. A. (2013) · CORE Scholar (Wright State University)
Chemical Modulation of AAV Trafficking
Berry, G. E. (2016) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/dpe3-gy73
2.6 Virotronics: Viruses as Tools for Functional Nanomaterials Design ☆
Jin, H., Chung, W., Sena, M., Merzlyak, A., & Lee, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803581-8.10168-7 · Cited by 1
Viral vectors for CNS disorders
Gray, S. J., Samulski, R. J., & Kalburgi, S. N. (2015) · doi:10.4155/9781909453937.fseb2013.13.23
Araya, B., & Fragaki, M. (2018) · HARVEST (University of Saskatchewan)
Engineering of Novel Adeno-Associated Virus Vectors for Gene Therapy Applications
Ortiz, S., & Luis, J. (2016) · Cited by 1
Xiao, P. (2013) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rn9x-xq74
Nicolson, S. C. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/gbv4-z740
AAV-Nrf2 Mediated Rescue of Oxidative Stress in Mouse Models
Liang, K. J. (2015) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/tmc2-r921
Improved Strategies for Directed Evolution of Adeno-Associated Virus Gene Therapy Vectors
Ojala, D. S. (2017) · eScholarship (California Digital Library)
徐, 增., 周, 秀., 石, 文., & 钱, 其. (2008) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb2008-53-21-2546
Metadata
- Authors
- Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V.
- Affiliations
- University of California, Berkeley (US)
- Abigail Wexner Research Institute (US)
- Corresponding author
- Schaffer, David V
- Venue
- Nature Biotechnology
- Published
- 2006-01-22
- Volume
- 24
- Issue
- 2
- Pages
- 198-204
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2102111681
- Cited by
- 538
- References
- 53
- Citations by year
- 2026: 20 · 2025: 20 · 2024: 29 · 2023: 31 · 2022: 31 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 19 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 32 · 2013: 31 · 2012: 23
- FWCI
- 15.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- ALS Association
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- adeno-associated virus, AAV2, directed evolution, viral capsid, gene delivery vectors, heparin binding, antibody neutralization, high-throughput selection
- MeSH terms
- Adenoviridae, Genetic Vectors, Transfection, Genetic Therapy, Drug Delivery Systems, Gene Targeting, Directed Molecular Evolution, Genetic Enhancement
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.